Records containing: Refractory Lymphoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-09-22MATCH Treatment Subprotocol F: Crizotinib in Patients With Tumors (Other Than Adenocarcinoma of Lung or ALCL) With ALK Rearrangements
-
CLINICAL_TRIALS study record update · 2021-08-17MATCH Treatment Subprotocol Z1A: Binimetinib in Patients With Tumors (Other Than Melanoma) With NRAS Mutations
-
CLINICAL_TRIALS study record update · 2021-08-16The Efficacy and Adverse Effect of Polatuzumab Vedotin in Patients With Diffuse Large B Cell Lymphoma: an Observation Study
-
CLINICAL_TRIALS study record update · 2021-08-10MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations
-
CLINICAL_TRIALS study record update · 2021-08-06Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2021-06-29MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients With Tumors With Aberrations in the FGFR Pathway
-
CLINICAL_TRIALS study record update · 2021-05-06Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
-
CLINICAL_TRIALS study record update · 2021-04-06MATCH Treatment Subprotocol Z1D: Nivolumab in Patients With Tumors With Mismatch Repair Deficiency
-
CLINICAL_TRIALS study record update · 2021-03-03MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations
-
CLINICAL_TRIALS study record update · 2021-02-05MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients With Tumors With HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)
-
CLINICAL_TRIALS study record update · 2021-01-26Clinical Trial of CD19/CD20 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2020-11-24A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma
-
CLINICAL_TRIALS study record update · 2020-09-28Phase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
-
CLINICAL_TRIALS study record update · 2020-07-20MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients With Tumors With DDR2 Mutations